阿斯利康中国首个呼吸生物制剂获批新适应证

澎湃新闻
Aug 07, 2025

8月7日,阿斯利康宣布,其中国首个呼吸生物制剂本瑞利珠单抗注射液(商品名:凡舒卓)新适应证在中国正式批准,用于儿童(6至<12岁)重度嗜酸粒细胞性哮喘(SEA)的维持治疗。本瑞利珠单抗是精准靶向嗜酸性粒细胞的抗IL-5R生物制剂,此前已在中国获批用于成人和12岁及以上青少年SEA的维持治疗。此次批准是基于全球多中心、开放标签的TATE三期临床试验的积极结果。在该临床试验中,本瑞利珠单抗达到了主要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10